Frits Van Rhee
Concepts (579)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Multiple Myeloma | 157 | 2024 | 2929 | 11.450 |
Why?
| Antibodies, Monoclonal | 26 | 2024 | 459 | 6.470 |
Why?
| Hematopoietic Stem Cell Transplantation | 28 | 2024 | 565 | 3.500 |
Why?
| Antineoplastic Agents | 18 | 2024 | 1171 | 3.410 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 42 | 2024 | 989 | 3.390 |
Why?
| Humans | 208 | 2024 | 49974 | 2.250 |
Why?
| Thalidomide | 24 | 2024 | 377 | 2.060 |
Why?
| Monoclonal Gammopathy of Undetermined Significance | 9 | 2023 | 103 | 1.910 |
Why?
| Neoplasm Recurrence, Local | 15 | 2024 | 614 | 1.880 |
Why?
| Immunotherapy, Adoptive | 9 | 2024 | 156 | 1.850 |
Why?
| Transplantation, Autologous | 26 | 2024 | 466 | 1.800 |
Why?
| Killer Cells, Natural | 7 | 2020 | 95 | 1.760 |
Why?
| Interleukin-6 | 12 | 2023 | 264 | 1.710 |
Why?
| Neoplasm Proteins | 13 | 2022 | 322 | 1.640 |
Why?
| Hematologic Neoplasms | 3 | 2022 | 99 | 1.630 |
Why?
| Middle Aged | 71 | 2024 | 12069 | 1.490 |
Why?
| Antigens, Neoplasm | 6 | 2014 | 151 | 1.480 |
Why?
| Clinical Trials as Topic | 13 | 2022 | 461 | 1.470 |
Why?
| Stem Cell Transplantation | 10 | 2022 | 181 | 1.400 |
Why?
| Prognosis | 44 | 2024 | 1942 | 1.310 |
Why?
| Gene Expression Regulation, Neoplastic | 20 | 2022 | 828 | 1.300 |
Why?
| Aged | 71 | 2024 | 9310 | 1.290 |
Why?
| Combined Modality Therapy | 19 | 2024 | 637 | 1.280 |
Why?
| Chromosomes, Human, Pair 1 | 9 | 2023 | 93 | 1.280 |
Why?
| Herpesvirus 8, Human | 7 | 2021 | 91 | 1.250 |
Why?
| Translocation, Genetic | 10 | 2022 | 264 | 1.210 |
Why?
| Treatment Outcome | 47 | 2024 | 5141 | 1.160 |
Why?
| B-Cell Maturation Antigen | 8 | 2024 | 90 | 1.160 |
Why?
| Boronic Acids | 12 | 2013 | 182 | 1.140 |
Why?
| Pyrazines | 12 | 2013 | 187 | 1.140 |
Why?
| Adult | 51 | 2024 | 13236 | 1.110 |
Why?
| Male | 80 | 2024 | 25241 | 1.100 |
Why?
| Female | 82 | 2024 | 26472 | 1.090 |
Why?
| Bone Marrow | 18 | 2024 | 362 | 1.080 |
Why?
| Proteasome Inhibitors | 5 | 2024 | 104 | 1.070 |
Why?
| Immunotherapy | 6 | 2024 | 238 | 1.020 |
Why?
| Gene Expression Profiling | 26 | 2023 | 1032 | 1.010 |
Why?
| Neoplasms, Second Primary | 2 | 2024 | 78 | 1.000 |
Why?
| Disease-Free Survival | 24 | 2019 | 454 | 0.960 |
Why?
| B-Lymphocytes | 5 | 2024 | 170 | 0.950 |
Why?
| Dexamethasone | 14 | 2024 | 430 | 0.930 |
Why?
| T-Lymphocytes, Cytotoxic | 4 | 2014 | 65 | 0.920 |
Why?
| Melphalan | 9 | 2020 | 174 | 0.900 |
Why?
| Cancer Vaccines | 3 | 2010 | 78 | 0.890 |
Why?
| Follow-Up Studies | 26 | 2024 | 2182 | 0.880 |
Why?
| Plasma Cells | 11 | 2023 | 223 | 0.860 |
Why?
| Hyperhidrosis | 1 | 2022 | 2 | 0.850 |
Why?
| Sweat | 1 | 2022 | 7 | 0.850 |
Why?
| Antibodies, Bispecific | 4 | 2024 | 60 | 0.830 |
Why?
| Survival Rate | 24 | 2020 | 894 | 0.830 |
Why?
| Lymphoma, B-Cell | 3 | 2022 | 63 | 0.810 |
Why?
| Drug Approval | 1 | 2022 | 47 | 0.810 |
Why?
| Ehrlichia chaffeensis | 1 | 2021 | 4 | 0.780 |
Why?
| Patient Participation | 1 | 2022 | 66 | 0.770 |
Why?
| Ehrlichiosis | 1 | 2021 | 15 | 0.770 |
Why?
| Cryosurgery | 1 | 2021 | 36 | 0.760 |
Why?
| T-Lymphocytes | 8 | 2024 | 338 | 0.760 |
Why?
| Immunoglobulin Light Chains | 3 | 2017 | 81 | 0.750 |
Why?
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 26 | 0.740 |
Why?
| Embolization, Therapeutic | 1 | 2021 | 88 | 0.720 |
Why?
| Cell Proliferation | 10 | 2023 | 1007 | 0.700 |
Why?
| Disease Progression | 16 | 2023 | 825 | 0.700 |
Why?
| Chromosomal Instability | 1 | 2019 | 16 | 0.680 |
Why?
| Neoplasms, Plasma Cell | 3 | 2024 | 37 | 0.670 |
Why?
| Membrane Proteins | 3 | 2006 | 341 | 0.670 |
Why?
| Adrenal Cortex Hormones | 2 | 2023 | 94 | 0.660 |
Why?
| Immunologic Factors | 2 | 2018 | 114 | 0.640 |
Why?
| Epigenesis, Genetic | 4 | 2023 | 374 | 0.630 |
Why?
| Neoplasm, Residual | 8 | 2022 | 165 | 0.630 |
Why?
| Chromosome Aberrations | 12 | 2023 | 297 | 0.620 |
Why?
| POEMS Syndrome | 1 | 2018 | 32 | 0.610 |
Why?
| Atrial Fibrillation | 2 | 2022 | 180 | 0.610 |
Why?
| Dendritic Cells | 3 | 2014 | 133 | 0.610 |
Why?
| Survival Analysis | 17 | 2023 | 653 | 0.610 |
Why?
| Thyroid Neoplasms | 1 | 2019 | 110 | 0.590 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2024 | 485 | 0.590 |
Why?
| Prealbumin | 2 | 2014 | 21 | 0.590 |
Why?
| Antibodies, Monoclonal, Humanized | 6 | 2023 | 225 | 0.570 |
Why?
| Positron-Emission Tomography | 7 | 2022 | 295 | 0.560 |
Why?
| Receptors, Interleukin-6 | 2 | 2014 | 22 | 0.560 |
Why?
| Cardiomyopathies | 2 | 2014 | 108 | 0.530 |
Why?
| Mutation | 10 | 2022 | 1294 | 0.520 |
Why?
| Osteolysis | 4 | 2022 | 75 | 0.490 |
Why?
| Immunotoxins | 1 | 2014 | 6 | 0.480 |
Why?
| Drug Resistance, Neoplasm | 7 | 2024 | 308 | 0.480 |
Why?
| Aged, 80 and over | 18 | 2024 | 3129 | 0.470 |
Why?
| Cytotoxicity, Immunologic | 2 | 2012 | 54 | 0.470 |
Why?
| Clonal Evolution | 3 | 2020 | 56 | 0.460 |
Why?
| Practice Guidelines as Topic | 4 | 2023 | 449 | 0.460 |
Why?
| Cyclophosphamide | 5 | 2021 | 165 | 0.440 |
Why?
| Transplantation, Homologous | 5 | 2017 | 139 | 0.440 |
Why?
| Amyloidosis | 1 | 2014 | 79 | 0.440 |
Why?
| Health Status | 1 | 2015 | 298 | 0.430 |
Why?
| Tumor Microenvironment | 5 | 2023 | 212 | 0.420 |
Why?
| Fluorodeoxyglucose F18 | 6 | 2021 | 192 | 0.420 |
Why?
| Recurrence | 12 | 2024 | 652 | 0.420 |
Why?
| Genome-Wide Association Study | 3 | 2024 | 166 | 0.410 |
Why?
| Remission Induction | 13 | 2021 | 207 | 0.410 |
Why?
| Risk Factors | 18 | 2021 | 3613 | 0.410 |
Why?
| Neutropenia | 2 | 2023 | 116 | 0.410 |
Why?
| Receptors, KIR | 2 | 2008 | 13 | 0.400 |
Why?
| Genetic Predisposition to Disease | 3 | 2024 | 510 | 0.390 |
Why?
| Pyrimidines | 2 | 2022 | 192 | 0.380 |
Why?
| Bone Diseases | 3 | 2021 | 99 | 0.380 |
Why?
| Dose-Response Relationship, Drug | 8 | 2020 | 1376 | 0.380 |
Why?
| Thrombocytopenia | 2 | 2022 | 85 | 0.380 |
Why?
| Azacitidine | 1 | 2010 | 34 | 0.380 |
Why?
| Benzamides | 1 | 2010 | 51 | 0.370 |
Why?
| Evolution, Molecular | 2 | 2021 | 99 | 0.360 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2010 | 53 | 0.360 |
Why?
| C-Reactive Protein | 6 | 2022 | 142 | 0.360 |
Why?
| Prednisone | 2 | 2021 | 99 | 0.350 |
Why?
| Doxorubicin | 6 | 2021 | 233 | 0.350 |
Why?
| TOR Serine-Threonine Kinases | 2 | 2020 | 77 | 0.340 |
Why?
| Drug Administration Schedule | 5 | 2015 | 376 | 0.340 |
Why?
| Chromosome Deletion | 5 | 2023 | 140 | 0.340 |
Why?
| Vaccination | 4 | 2022 | 266 | 0.330 |
Why?
| Metaphase | 4 | 2016 | 44 | 0.330 |
Why?
| Pelvis | 2 | 2021 | 68 | 0.330 |
Why?
| Quality of Life | 1 | 2015 | 836 | 0.330 |
Why?
| Membrane Glycoproteins | 2 | 2009 | 240 | 0.320 |
Why?
| Paraproteinemias | 3 | 2022 | 72 | 0.320 |
Why?
| Proportional Hazards Models | 7 | 2024 | 402 | 0.320 |
Why?
| Animals | 15 | 2024 | 13187 | 0.310 |
Why?
| Placebo Effect | 2 | 2020 | 17 | 0.310 |
Why?
| Bone Neoplasms | 4 | 2013 | 179 | 0.310 |
Why?
| Adoptive Transfer | 1 | 2007 | 40 | 0.300 |
Why?
| Histocompatibility Antigens Class I | 1 | 2007 | 44 | 0.300 |
Why?
| Chromatin | 3 | 2023 | 151 | 0.300 |
Why?
| Cytogenetic Analysis | 5 | 2023 | 82 | 0.290 |
Why?
| DNA Methylation | 4 | 2023 | 548 | 0.290 |
Why?
| Boron Compounds | 2 | 2024 | 19 | 0.280 |
Why?
| Risk Assessment | 9 | 2022 | 1259 | 0.280 |
Why?
| Chromans | 2 | 2024 | 37 | 0.280 |
Why?
| Vincristine | 3 | 2021 | 89 | 0.280 |
Why?
| Mice, SCID | 6 | 2013 | 175 | 0.280 |
Why?
| Cell Membrane | 1 | 2007 | 248 | 0.280 |
Why?
| Glycine | 2 | 2024 | 75 | 0.280 |
Why?
| Down-Regulation | 1 | 2007 | 348 | 0.270 |
Why?
| Angiogenesis Inhibitors | 5 | 2010 | 187 | 0.270 |
Why?
| In Situ Hybridization, Fluorescence | 5 | 2023 | 259 | 0.270 |
Why?
| Neoplasm Staging | 6 | 2024 | 740 | 0.260 |
Why?
| Cell Line, Tumor | 9 | 2023 | 1403 | 0.260 |
Why?
| Disease Management | 2 | 2018 | 174 | 0.260 |
Why?
| Chromosomes, Human, Pair 17 | 2 | 2017 | 36 | 0.260 |
Why?
| Transplantation Conditioning | 5 | 2008 | 83 | 0.260 |
Why?
| Vitamin E | 2 | 2024 | 81 | 0.260 |
Why?
| Case-Control Studies | 6 | 2024 | 1131 | 0.260 |
Why?
| Infusions, Intravenous | 3 | 2015 | 206 | 0.260 |
Why?
| Mice | 11 | 2024 | 5739 | 0.250 |
Why?
| Bone Resorption | 2 | 2022 | 304 | 0.250 |
Why?
| Antibody Formation | 1 | 2005 | 54 | 0.250 |
Why?
| Fever | 2 | 2022 | 114 | 0.250 |
Why?
| Registries | 3 | 2024 | 522 | 0.240 |
Why?
| Polycomb Repressive Complex 2 | 2 | 2021 | 47 | 0.240 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2020 | 116 | 0.240 |
Why?
| Time Factors | 11 | 2021 | 2903 | 0.240 |
Why?
| Pentaerythritol Tetranitrate | 1 | 2024 | 6 | 0.240 |
Why?
| Flow Cytometry | 4 | 2012 | 476 | 0.230 |
Why?
| Monocytes | 2 | 2020 | 131 | 0.230 |
Why?
| Gene Expression | 2 | 2018 | 609 | 0.230 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2024 | 92 | 0.230 |
Why?
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 169 | 0.230 |
Why?
| Cell Cycle Proteins | 2 | 2022 | 166 | 0.230 |
Why?
| Proteasome Endopeptidase Complex | 3 | 2011 | 114 | 0.220 |
Why?
| Blotting, Western | 3 | 2015 | 601 | 0.220 |
Why?
| Epstein-Barr Virus Infections | 2 | 2020 | 30 | 0.220 |
Why?
| Signal Transduction | 6 | 2021 | 1618 | 0.220 |
Why?
| Integrin beta Chains | 1 | 2023 | 14 | 0.220 |
Why?
| Radiation-Protective Agents | 1 | 2024 | 74 | 0.220 |
Why?
| Prospective Studies | 8 | 2022 | 2364 | 0.220 |
Why?
| Integrins | 1 | 2023 | 31 | 0.220 |
Why?
| Young Adult | 5 | 2020 | 3958 | 0.220 |
Why?
| Cross-Sectional Studies | 3 | 2023 | 1557 | 0.220 |
Why?
| Double-Blind Method | 2 | 2015 | 681 | 0.210 |
Why?
| Sweating | 1 | 2022 | 7 | 0.210 |
Why?
| Hematopoietic Stem Cells | 2 | 2022 | 184 | 0.210 |
Why?
| Consensus | 2 | 2020 | 148 | 0.210 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2020 | 79 | 0.210 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2017 | 202 | 0.210 |
Why?
| DNA, Intergenic | 1 | 2022 | 7 | 0.200 |
Why?
| Kaplan-Meier Estimate | 10 | 2016 | 466 | 0.200 |
Why?
| Tumor Cells, Cultured | 4 | 2013 | 465 | 0.200 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2022 | 51 | 0.200 |
Why?
| Immunoconjugates | 1 | 2022 | 38 | 0.200 |
Why?
| United States | 4 | 2022 | 4860 | 0.200 |
Why?
| Waldenstrom Macroglobulinemia | 1 | 2022 | 40 | 0.200 |
Why?
| Proteomics | 3 | 2021 | 329 | 0.200 |
Why?
| United States Food and Drug Administration | 1 | 2022 | 93 | 0.200 |
Why?
| Influenza, Human | 1 | 2022 | 84 | 0.200 |
Why?
| Epigenomics | 1 | 2021 | 67 | 0.200 |
Why?
| Mediastinum | 1 | 2021 | 22 | 0.200 |
Why?
| Chromosomes, Human, Pair 14 | 3 | 2020 | 75 | 0.200 |
Why?
| Receptors, Glucocorticoid | 2 | 2012 | 32 | 0.190 |
Why?
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 141 | 0.190 |
Why?
| Ubiquitination | 1 | 2021 | 43 | 0.190 |
Why?
| Apoptosis | 5 | 2018 | 1101 | 0.190 |
Why?
| Axilla | 1 | 2021 | 89 | 0.190 |
Why?
| Alleles | 3 | 2021 | 250 | 0.190 |
Why?
| Multiple Organ Failure | 1 | 2021 | 47 | 0.190 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 92 | 0.190 |
Why?
| Proto-Oncogene Proteins c-maf | 2 | 2020 | 19 | 0.190 |
Why?
| Diffusion Magnetic Resonance Imaging | 2 | 2019 | 123 | 0.190 |
Why?
| Salvage Therapy | 6 | 2013 | 139 | 0.190 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 105 | 0.190 |
Why?
| Epstein-Barr Virus Nuclear Antigens | 1 | 2020 | 1 | 0.190 |
Why?
| Rare Diseases | 1 | 2020 | 44 | 0.190 |
Why?
| Interferon-gamma | 3 | 2014 | 177 | 0.180 |
Why?
| Genes, Tumor Suppressor | 2 | 2021 | 73 | 0.180 |
Why?
| Longitudinal Studies | 5 | 2024 | 688 | 0.180 |
Why?
| Cytokines | 2 | 2014 | 612 | 0.180 |
Why?
| Cell Cycle | 1 | 2021 | 231 | 0.180 |
Why?
| Radiopharmaceuticals | 4 | 2021 | 209 | 0.180 |
Why?
| Interferon Type I | 1 | 2020 | 25 | 0.180 |
Why?
| Exosome Multienzyme Ribonuclease Complex | 1 | 2020 | 12 | 0.180 |
Why?
| Myelodysplastic Syndromes | 2 | 2013 | 81 | 0.180 |
Why?
| Leukemia, Plasma Cell | 1 | 2020 | 33 | 0.180 |
Why?
| Research Design | 2 | 2020 | 344 | 0.180 |
Why?
| Multivariate Analysis | 8 | 2021 | 577 | 0.170 |
Why?
| Gene Amplification | 1 | 2019 | 57 | 0.170 |
Why?
| Health Status Disparities | 1 | 2022 | 195 | 0.170 |
Why?
| Measles virus | 1 | 2019 | 8 | 0.170 |
Why?
| Genomics | 4 | 2023 | 286 | 0.170 |
Why?
| Measles | 1 | 2019 | 7 | 0.170 |
Why?
| Gene Regulatory Networks | 1 | 2020 | 107 | 0.170 |
Why?
| Hematopoiesis, Extramedullary | 1 | 2019 | 9 | 0.170 |
Why?
| Data Collection | 1 | 2020 | 279 | 0.170 |
Why?
| DNA | 1 | 2023 | 541 | 0.170 |
Why?
| Immunohistochemistry | 2 | 2015 | 973 | 0.170 |
Why?
| Oncolytic Virotherapy | 1 | 2019 | 16 | 0.170 |
Why?
| Biopsy | 5 | 2018 | 584 | 0.170 |
Why?
| Healthcare Disparities | 1 | 2022 | 257 | 0.170 |
Why?
| Patient Safety | 1 | 2020 | 102 | 0.170 |
Why?
| Sirolimus | 1 | 2019 | 62 | 0.160 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2018 | 10 | 0.160 |
Why?
| Precancerous Conditions | 2 | 2010 | 83 | 0.160 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 157 | 0.160 |
Why?
| Cell Differentiation | 6 | 2022 | 651 | 0.160 |
Why?
| Evidence-Based Medicine | 2 | 2018 | 247 | 0.160 |
Why?
| Syndrome | 1 | 2019 | 237 | 0.160 |
Why?
| Graft vs Host Disease | 4 | 2007 | 75 | 0.160 |
Why?
| MafB Transcription Factor | 1 | 2018 | 9 | 0.160 |
Why?
| Spleen | 1 | 2019 | 172 | 0.160 |
Why?
| Phosphotransferases | 1 | 2018 | 16 | 0.160 |
Why?
| Genomic Instability | 2 | 2016 | 92 | 0.160 |
Why?
| Immunomodulation | 1 | 2018 | 37 | 0.160 |
Why?
| Chemokines | 1 | 2018 | 77 | 0.150 |
Why?
| Plasma | 1 | 2018 | 43 | 0.150 |
Why?
| Myeloablative Agonists | 2 | 2008 | 30 | 0.150 |
Why?
| Hematopoietic Stem Cell Mobilization | 2 | 2008 | 57 | 0.150 |
Why?
| Genes, Neoplasm | 2 | 2015 | 30 | 0.150 |
Why?
| Adipocytes | 1 | 2018 | 121 | 0.150 |
Why?
| Magnetic Resonance Imaging | 5 | 2013 | 1537 | 0.150 |
Why?
| Osteoclasts | 3 | 2022 | 425 | 0.150 |
Why?
| Gene Dosage | 2 | 2015 | 78 | 0.150 |
Why?
| Models, Biological | 2 | 2018 | 727 | 0.150 |
Why?
| Gene Rearrangement | 1 | 2018 | 74 | 0.150 |
Why?
| Hexokinase | 1 | 2017 | 17 | 0.150 |
Why?
| Communication | 1 | 2019 | 246 | 0.150 |
Why?
| Heterozygote | 2 | 2014 | 81 | 0.140 |
Why?
| HLA-A Antigens | 2 | 2007 | 10 | 0.140 |
Why?
| Calcification, Physiologic | 1 | 2017 | 41 | 0.140 |
Why?
| Protein-Tyrosine Kinases | 2 | 2018 | 95 | 0.140 |
Why?
| Drug Therapy, Combination | 1 | 2018 | 377 | 0.140 |
Why?
| Oligonucleotide Array Sequence Analysis | 5 | 2010 | 411 | 0.140 |
Why?
| Gene Frequency | 2 | 2013 | 94 | 0.140 |
Why?
| Transcriptome | 4 | 2020 | 315 | 0.130 |
Why?
| Syndecan-1 | 4 | 2021 | 72 | 0.130 |
Why?
| Critical Illness | 1 | 2018 | 288 | 0.130 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2017 | 181 | 0.130 |
Why?
| Lymphocyte Activation | 2 | 2017 | 172 | 0.130 |
Why?
| Confidence Intervals | 2 | 2014 | 156 | 0.130 |
Why?
| Adolescent | 5 | 2020 | 6356 | 0.130 |
Why?
| Tumor Burden | 3 | 2020 | 132 | 0.130 |
Why?
| Immunity, Innate | 1 | 2016 | 104 | 0.130 |
Why?
| Erythrocyte Indices | 1 | 2015 | 7 | 0.130 |
Why?
| Biomarkers, Pharmacological | 2 | 2012 | 25 | 0.130 |
Why?
| DNA Copy Number Variations | 3 | 2022 | 110 | 0.130 |
Why?
| Coculture Techniques | 2 | 2013 | 146 | 0.130 |
Why?
| Hemoglobins | 2 | 2013 | 107 | 0.130 |
Why?
| Cysteine-Rich Protein 61 | 1 | 2014 | 3 | 0.120 |
Why?
| International Cooperation | 1 | 2014 | 44 | 0.120 |
Why?
| Half-Life | 1 | 2014 | 84 | 0.120 |
Why?
| Hematologic Diseases | 1 | 2014 | 22 | 0.120 |
Why?
| Fatigue | 1 | 2015 | 117 | 0.120 |
Why?
| Iron | 1 | 2015 | 122 | 0.120 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 244 | 0.120 |
Why?
| Area Under Curve | 1 | 2014 | 182 | 0.120 |
Why?
| Amyloid Neuropathies, Familial | 1 | 2013 | 5 | 0.120 |
Why?
| Antibodies | 2 | 2024 | 154 | 0.120 |
Why?
| Reference Values | 1 | 2014 | 310 | 0.110 |
Why?
| ROC Curve | 1 | 2014 | 232 | 0.110 |
Why?
| Severity of Illness Index | 2 | 2014 | 945 | 0.110 |
Why?
| Emotions | 1 | 2015 | 165 | 0.110 |
Why?
| Renal Insufficiency | 2 | 2021 | 109 | 0.110 |
Why?
| Antineoplastic Agents, Alkylating | 3 | 2008 | 74 | 0.110 |
Why?
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 42 | 0.110 |
Why?
| Disease Models, Animal | 2 | 2016 | 1455 | 0.110 |
Why?
| Administration, Metronomic | 1 | 2013 | 7 | 0.110 |
Why?
| Cystatin M | 2 | 2024 | 20 | 0.110 |
Why?
| Retrospective Studies | 7 | 2024 | 6108 | 0.110 |
Why?
| Inflammation Mediators | 1 | 2014 | 112 | 0.110 |
Why?
| Cisplatin | 4 | 2013 | 278 | 0.110 |
Why?
| Macaca mulatta | 2 | 2024 | 93 | 0.110 |
Why?
| Nicotinamide Phosphoribosyltransferase | 1 | 2013 | 5 | 0.110 |
Why?
| Central Nervous System Neoplasms | 1 | 2013 | 63 | 0.110 |
Why?
| Oligopeptides | 1 | 2013 | 89 | 0.110 |
Why?
| beta Catenin | 1 | 2013 | 102 | 0.110 |
Why?
| Lymph Nodes | 3 | 2021 | 260 | 0.110 |
Why?
| Antibody-Dependent Cell Cytotoxicity | 2 | 2009 | 12 | 0.110 |
Why?
| Venous Thrombosis | 2 | 2004 | 90 | 0.110 |
Why?
| Myelolipoma | 1 | 2012 | 9 | 0.110 |
Why?
| Leukemia | 1 | 2013 | 65 | 0.110 |
Why?
| Mental Health | 1 | 2015 | 219 | 0.110 |
Why?
| Cell Survival | 2 | 2020 | 600 | 0.100 |
Why?
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 8 | 0.100 |
Why?
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 9 | 0.100 |
Why?
| Clone Cells | 2 | 2023 | 74 | 0.100 |
Why?
| Maintenance Chemotherapy | 1 | 2012 | 49 | 0.100 |
Why?
| Pain | 1 | 2015 | 379 | 0.100 |
Why?
| Adaptor Proteins, Signal Transducing | 2 | 2024 | 197 | 0.100 |
Why?
| Interleukin-2 | 1 | 2012 | 72 | 0.100 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2013 | 201 | 0.100 |
Why?
| Models, Genetic | 2 | 2016 | 170 | 0.100 |
Why?
| Mice, Inbred NOD | 1 | 2012 | 96 | 0.100 |
Why?
| Cell Movement | 1 | 2013 | 247 | 0.100 |
Why?
| Immunoenzyme Techniques | 1 | 2012 | 143 | 0.100 |
Why?
| Hemangioma | 1 | 2013 | 83 | 0.100 |
Why?
| Soft Tissue Neoplasms | 1 | 2012 | 57 | 0.100 |
Why?
| Genotype | 1 | 2013 | 537 | 0.100 |
Why?
| Arkansas | 5 | 2021 | 1977 | 0.100 |
Why?
| Transcriptional Elongation Factors | 2 | 2022 | 18 | 0.100 |
Why?
| Transduction, Genetic | 2 | 2014 | 45 | 0.100 |
Why?
| Chemokine CXCL13 | 2 | 2022 | 5 | 0.090 |
Why?
| Models, Statistical | 2 | 2014 | 224 | 0.090 |
Why?
| Peripheral Blood Stem Cell Transplantation | 2 | 2008 | 53 | 0.090 |
Why?
| Mutation Rate | 2 | 2021 | 36 | 0.090 |
Why?
| Immunoglobulin Idiotypes | 1 | 2010 | 5 | 0.090 |
Why?
| CD40 Ligand | 1 | 2010 | 14 | 0.090 |
Why?
| Hypersensitivity, Delayed | 1 | 2010 | 21 | 0.090 |
Why?
| Secondary Prevention | 1 | 2010 | 78 | 0.090 |
Why?
| Interleukin-4 | 1 | 2010 | 43 | 0.090 |
Why?
| Up-Regulation | 4 | 2018 | 452 | 0.090 |
Why?
| HIV Seropositivity | 1 | 2010 | 27 | 0.090 |
Why?
| Eukaryotic Initiation Factor-2 | 1 | 2010 | 18 | 0.090 |
Why?
| Adjuvants, Immunologic | 1 | 2010 | 51 | 0.090 |
Why?
| Immunity, Cellular | 1 | 2010 | 69 | 0.090 |
Why?
| Cell Line | 2 | 2013 | 1000 | 0.090 |
Why?
| Cells, Cultured | 3 | 2013 | 1573 | 0.090 |
Why?
| Etoposide | 2 | 2007 | 72 | 0.090 |
Why?
| Ovarian Neoplasms | 1 | 2014 | 447 | 0.090 |
Why?
| Placenta | 1 | 2011 | 132 | 0.090 |
Why?
| Transplantation, Heterologous | 1 | 2009 | 74 | 0.080 |
Why?
| Radiography | 4 | 2012 | 489 | 0.080 |
Why?
| Hospitalization | 2 | 2024 | 652 | 0.080 |
Why?
| Polymerase Chain Reaction | 1 | 2010 | 453 | 0.080 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 2008 | 28 | 0.080 |
Why?
| Histones | 2 | 2021 | 312 | 0.080 |
Why?
| Bone and Bones | 3 | 2021 | 469 | 0.080 |
Why?
| Transcription Factors | 2 | 2023 | 561 | 0.080 |
Why?
| Lymphocyte Subsets | 1 | 2008 | 13 | 0.080 |
Why?
| Haplotypes | 1 | 2008 | 83 | 0.080 |
Why?
| Immunoglobulin lambda-Chains | 1 | 2008 | 15 | 0.080 |
Why?
| Liver Neoplasms | 1 | 2012 | 326 | 0.080 |
Why?
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 61 | 0.080 |
Why?
| Cytogenetics | 1 | 2008 | 23 | 0.080 |
Why?
| Gene Deletion | 1 | 2009 | 266 | 0.080 |
Why?
| Receptors, Immunologic | 1 | 2008 | 37 | 0.080 |
Why?
| Ligands | 1 | 2008 | 204 | 0.080 |
Why?
| Neoplastic Stem Cells | 1 | 2009 | 103 | 0.080 |
Why?
| Osteogenesis | 1 | 2011 | 352 | 0.080 |
Why?
| Twins | 1 | 2007 | 33 | 0.080 |
Why?
| Busulfan | 1 | 2007 | 18 | 0.080 |
Why?
| Herpesviridae Infections | 2 | 2019 | 46 | 0.070 |
Why?
| Diphosphonates | 1 | 2008 | 90 | 0.070 |
Why?
| Immunophenotyping | 1 | 2007 | 109 | 0.070 |
Why?
| Leukocytes, Mononuclear | 1 | 2007 | 116 | 0.070 |
Why?
| Caspases | 2 | 2018 | 104 | 0.070 |
Why?
| Antimetabolites | 1 | 2006 | 13 | 0.070 |
Why?
| Creatinine | 1 | 2007 | 139 | 0.070 |
Why?
| Blood Proteins | 1 | 2007 | 82 | 0.070 |
Why?
| Skin Neoplasms | 1 | 2012 | 488 | 0.070 |
Why?
| Immunosuppressive Agents | 1 | 2008 | 221 | 0.070 |
Why?
| Antibodies, Neoplasm | 1 | 2006 | 28 | 0.070 |
Why?
| Graft vs Leukemia Effect | 1 | 2006 | 2 | 0.070 |
Why?
| Chromosome Banding | 1 | 2006 | 24 | 0.070 |
Why?
| Plasmacytoma | 1 | 2006 | 42 | 0.070 |
Why?
| Cohort Studies | 3 | 2020 | 1422 | 0.070 |
Why?
| MicroRNAs | 1 | 2010 | 353 | 0.070 |
Why?
| Amiloride | 1 | 2005 | 8 | 0.070 |
Why?
| HLA-A2 Antigen | 1 | 2005 | 11 | 0.070 |
Why?
| Bone Marrow Transplantation | 2 | 2022 | 116 | 0.070 |
Why?
| Imaging, Three-Dimensional | 2 | 2017 | 151 | 0.070 |
Why?
| Sensitivity and Specificity | 1 | 2007 | 861 | 0.060 |
Why?
| Predictive Value of Tests | 3 | 2018 | 903 | 0.060 |
Why?
| Poly(ADP-ribose) Polymerases | 2 | 2016 | 30 | 0.060 |
Why?
| Tomography, X-Ray Computed | 2 | 2023 | 1159 | 0.060 |
Why?
| Transmembrane Activator and CAML Interactor Protein | 1 | 2024 | 6 | 0.060 |
Why?
| Mendelian Randomization Analysis | 1 | 2024 | 7 | 0.060 |
Why?
| Phthalimides | 1 | 2024 | 4 | 0.060 |
Why?
| Piperidones | 1 | 2024 | 5 | 0.060 |
Why?
| Enoxaparin | 1 | 2004 | 27 | 0.060 |
Why?
| Telomere | 1 | 2024 | 36 | 0.060 |
Why?
| Retreatment | 1 | 2024 | 57 | 0.060 |
Why?
| Ferritins | 1 | 2024 | 30 | 0.060 |
Why?
| NF-kappa B | 2 | 2018 | 314 | 0.060 |
Why?
| Morpholines | 1 | 2024 | 71 | 0.060 |
Why?
| Myeloid Progenitor Cells | 1 | 2023 | 18 | 0.060 |
Why?
| X-Ray Microtomography | 1 | 2024 | 77 | 0.060 |
Why?
| Cost of Illness | 1 | 2024 | 117 | 0.060 |
Why?
| Neoplasms | 1 | 2014 | 1235 | 0.060 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2024 | 53 | 0.060 |
Why?
| Epidemiologic Methods | 3 | 2008 | 49 | 0.060 |
Why?
| DNA, Neoplasm | 2 | 2020 | 147 | 0.060 |
Why?
| Fibroblasts | 1 | 2005 | 345 | 0.060 |
Why?
| Gene Silencing | 2 | 2016 | 119 | 0.060 |
Why?
| Cell Communication | 1 | 2023 | 69 | 0.050 |
Why?
| Cluster Analysis | 3 | 2010 | 235 | 0.050 |
Why?
| TNF Receptor-Associated Factor 3 | 1 | 2022 | 13 | 0.050 |
Why?
| Patients | 1 | 2022 | 49 | 0.050 |
Why?
| Geography | 1 | 2022 | 61 | 0.050 |
Why?
| Myeloid Differentiation Factor 88 | 1 | 2022 | 33 | 0.050 |
Why?
| Guanine Nucleotide Exchange Factors | 1 | 2022 | 17 | 0.050 |
Why?
| Whole-Body Irradiation | 1 | 2022 | 131 | 0.050 |
Why?
| Inheritance Patterns | 1 | 2022 | 22 | 0.050 |
Why?
| Quantitative Trait Loci | 1 | 2022 | 42 | 0.050 |
Why?
| Primary Cell Culture | 1 | 2022 | 61 | 0.050 |
Why?
| Patient Selection | 1 | 2023 | 253 | 0.050 |
Why?
| Chromosomal Proteins, Non-Histone | 1 | 2022 | 40 | 0.050 |
Why?
| Oncogenes | 1 | 2021 | 57 | 0.050 |
Why?
| Risk | 2 | 2014 | 320 | 0.050 |
Why?
| Anticoagulants | 1 | 2004 | 250 | 0.050 |
Why?
| Phylogeny | 1 | 2022 | 235 | 0.050 |
Why?
| Age of Onset | 2 | 2013 | 108 | 0.050 |
Why?
| Child, Preschool | 2 | 2020 | 3871 | 0.050 |
Why?
| RANK Ligand | 1 | 2022 | 179 | 0.050 |
Why?
| SOXC Transcription Factors | 1 | 2021 | 13 | 0.050 |
Why?
| Rabbits | 2 | 2013 | 370 | 0.050 |
Why?
| Polymorphism, Genetic | 1 | 2022 | 181 | 0.050 |
Why?
| Transcriptional Activation | 1 | 2021 | 121 | 0.050 |
Why?
| Fibrosis | 1 | 2021 | 179 | 0.050 |
Why?
| Edema | 1 | 2021 | 67 | 0.050 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 66 | 0.050 |
Why?
| Cyclin D2 | 1 | 2020 | 20 | 0.050 |
Why?
| Aneuploidy | 1 | 2020 | 16 | 0.050 |
Why?
| Spatio-Temporal Analysis | 1 | 2020 | 10 | 0.050 |
Why?
| Base Sequence | 1 | 2022 | 643 | 0.050 |
Why?
| Chromosomes, Human, Pair 4 | 1 | 2020 | 31 | 0.050 |
Why?
| Repressor Proteins | 1 | 2022 | 151 | 0.050 |
Why?
| Gene Expression Regulation, Leukemic | 1 | 2020 | 33 | 0.050 |
Why?
| Chromosomes, Human, Pair 11 | 1 | 2020 | 54 | 0.050 |
Why?
| Histone Code | 1 | 2020 | 32 | 0.050 |
Why?
| Cyclin D1 | 1 | 2020 | 56 | 0.050 |
Why?
| ras Proteins | 1 | 2020 | 64 | 0.050 |
Why?
| Genome, Human | 1 | 2021 | 111 | 0.050 |
Why?
| Protein Kinase Inhibitors | 1 | 2022 | 204 | 0.040 |
Why?
| Single-Cell Analysis | 1 | 2020 | 57 | 0.040 |
Why?
| Genetic Loci | 1 | 2020 | 49 | 0.040 |
Why?
| Mice, Transgenic | 1 | 2021 | 555 | 0.040 |
Why?
| False Negative Reactions | 1 | 2019 | 30 | 0.040 |
Why?
| DNA Mutational Analysis | 1 | 2020 | 175 | 0.040 |
Why?
| Genetic Variation | 1 | 2020 | 213 | 0.040 |
Why?
| Neoplasm Invasiveness | 1 | 2020 | 267 | 0.040 |
Why?
| Incidence | 2 | 2013 | 1003 | 0.040 |
Why?
| Herpesvirus 4, Human | 1 | 2019 | 35 | 0.040 |
Why?
| Europe | 1 | 2019 | 74 | 0.040 |
Why?
| Communicable Disease Control | 1 | 2019 | 39 | 0.040 |
Why?
| beta 2-Microglobulin | 2 | 2009 | 38 | 0.040 |
Why?
| Computational Biology | 1 | 2020 | 214 | 0.040 |
Why?
| RNA, Messenger | 2 | 2016 | 1105 | 0.040 |
Why?
| Virus Diseases | 1 | 2019 | 39 | 0.040 |
Why?
| Genome, Viral | 1 | 2019 | 79 | 0.040 |
Why?
| DNA, Viral | 1 | 2019 | 133 | 0.040 |
Why?
| Fibrinogen | 1 | 2018 | 31 | 0.040 |
Why?
| Immunoglobulin A | 1 | 2018 | 45 | 0.040 |
Why?
| Glycogen Synthase Kinase 3 | 1 | 2018 | 20 | 0.040 |
Why?
| Bone Marrow Cells | 2 | 2014 | 191 | 0.040 |
Why?
| Platelet Count | 2 | 2008 | 72 | 0.040 |
Why?
| Pathology, Molecular | 1 | 2018 | 22 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 427 | 0.040 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 51 | 0.040 |
Why?
| Promoter Regions, Genetic | 1 | 2020 | 475 | 0.040 |
Why?
| Immunoglobulin G | 1 | 2018 | 186 | 0.040 |
Why?
| Oncogene Proteins, Fusion | 1 | 2018 | 58 | 0.040 |
Why?
| Data Interpretation, Statistical | 2 | 2010 | 158 | 0.040 |
Why?
| Databases, Factual | 2 | 2013 | 658 | 0.040 |
Why?
| Child | 2 | 2020 | 6847 | 0.040 |
Why?
| Kidney Function Tests | 1 | 2017 | 49 | 0.040 |
Why?
| False Positive Reactions | 1 | 2017 | 63 | 0.040 |
Why?
| Glomerular Filtration Rate | 1 | 2017 | 111 | 0.040 |
Why?
| Lamins | 1 | 2016 | 5 | 0.040 |
Why?
| Cell Transformation, Neoplastic | 1 | 2018 | 177 | 0.040 |
Why?
| Chromosomes, Human, Pair 16 | 1 | 2016 | 19 | 0.040 |
Why?
| Internationality | 1 | 2017 | 36 | 0.040 |
Why?
| Amino Acid Sequence | 1 | 2018 | 585 | 0.040 |
Why?
| Alkaline Phosphatase | 1 | 2017 | 94 | 0.040 |
Why?
| Genes, ras | 1 | 2016 | 43 | 0.030 |
Why?
| Genes, p53 | 1 | 2016 | 51 | 0.030 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 78 | 0.030 |
Why?
| Glycolysis | 1 | 2016 | 70 | 0.030 |
Why?
| Proteolysis | 1 | 2016 | 94 | 0.030 |
Why?
| Enzyme Activation | 1 | 2016 | 276 | 0.030 |
Why?
| Chromosome Mapping | 2 | 2006 | 156 | 0.030 |
Why?
| Prevalence | 1 | 2019 | 944 | 0.030 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2016 | 106 | 0.030 |
Why?
| Phosphorylation | 1 | 2016 | 535 | 0.030 |
Why?
| Kidney Diseases | 1 | 2017 | 214 | 0.030 |
Why?
| Gene Fusion | 1 | 2014 | 9 | 0.030 |
Why?
| Asymptomatic Diseases | 1 | 2014 | 36 | 0.030 |
Why?
| Myocardium | 1 | 2017 | 436 | 0.030 |
Why?
| Interspersed Repetitive Sequences | 1 | 2014 | 8 | 0.030 |
Why?
| Karyotype | 1 | 2014 | 18 | 0.030 |
Why?
| Capsid | 1 | 2014 | 3 | 0.030 |
Why?
| Lymphocyte Culture Test, Mixed | 1 | 2014 | 7 | 0.030 |
Why?
| HIV-1 | 1 | 2014 | 55 | 0.030 |
Why?
| Homozygote | 1 | 2013 | 56 | 0.030 |
Why?
| Cerebrospinal Fluid | 1 | 2013 | 32 | 0.030 |
Why?
| Genetic Vectors | 1 | 2014 | 125 | 0.030 |
Why?
| Nicotinamide Mononucleotide | 1 | 2013 | 3 | 0.030 |
Why?
| Acrylamides | 1 | 2013 | 6 | 0.030 |
Why?
| Diagnosis, Differential | 1 | 2017 | 1037 | 0.030 |
Why?
| Receptors, CXCR4 | 1 | 2013 | 28 | 0.030 |
Why?
| Niacinamide | 1 | 2013 | 22 | 0.030 |
Why?
| Dependovirus | 1 | 2014 | 101 | 0.030 |
Why?
| Amides | 1 | 2013 | 34 | 0.030 |
Why?
| NAD | 1 | 2013 | 43 | 0.030 |
Why?
| Enzyme Induction | 1 | 2013 | 80 | 0.030 |
Why?
| Sirtuin 1 | 1 | 2013 | 28 | 0.030 |
Why?
| Chemokine CXCL12 | 1 | 2013 | 32 | 0.030 |
Why?
| Nitriles | 1 | 2013 | 54 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2013 | 106 | 0.030 |
Why?
| Transplantation Chimera | 2 | 2003 | 15 | 0.030 |
Why?
| RNA, Small Interfering | 1 | 2013 | 215 | 0.030 |
Why?
| Infant | 1 | 2020 | 3567 | 0.030 |
Why?
| Piperidines | 1 | 2013 | 98 | 0.030 |
Why?
| Induction Chemotherapy | 1 | 2012 | 60 | 0.030 |
Why?
| Lymphocyte Count | 1 | 2011 | 21 | 0.030 |
Why?
| Chemokine CXCL10 | 1 | 2011 | 19 | 0.030 |
Why?
| Acute Disease | 1 | 2013 | 366 | 0.030 |
Why?
| HIV Infections | 1 | 2016 | 357 | 0.030 |
Why?
| Antibodies, Neutralizing | 1 | 2011 | 64 | 0.020 |
Why?
| Sex Factors | 1 | 2013 | 691 | 0.020 |
Why?
| Pharmacogenetics | 1 | 2011 | 52 | 0.020 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2010 | 25 | 0.020 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2010 | 43 | 0.020 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2010 | 43 | 0.020 |
Why?
| Microarray Analysis | 1 | 2010 | 73 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2013 | 391 | 0.020 |
Why?
| International Classification of Diseases | 1 | 2010 | 64 | 0.020 |
Why?
| Argonaute Proteins | 1 | 2010 | 11 | 0.020 |
Why?
| RNA-Binding Proteins | 1 | 2011 | 123 | 0.020 |
Why?
| Oligonucleotides | 1 | 2010 | 80 | 0.020 |
Why?
| Polyploidy | 1 | 2009 | 11 | 0.020 |
Why?
| Bone Marrow Examination | 1 | 2009 | 11 | 0.020 |
Why?
| L-Lactate Dehydrogenase | 1 | 2009 | 65 | 0.020 |
Why?
| Neoplasm Metastasis | 1 | 2009 | 231 | 0.020 |
Why?
| Ploidies | 1 | 2008 | 11 | 0.020 |
Why?
| Chromosomes, Human, Pair 13 | 1 | 2008 | 38 | 0.020 |
Why?
| Serum Albumin | 1 | 2008 | 58 | 0.020 |
Why?
| Polyethylene Glycols | 1 | 2008 | 93 | 0.020 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2010 | 549 | 0.020 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2008 | 211 | 0.020 |
Why?
| Age Distribution | 1 | 2007 | 168 | 0.020 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2007 | 47 | 0.020 |
Why?
| Recombinant Proteins | 1 | 2008 | 486 | 0.020 |
Why?
| Multigene Family | 1 | 2006 | 56 | 0.020 |
Why?
| Cyclin D | 1 | 2006 | 18 | 0.020 |
Why?
| Syndecans | 1 | 2006 | 34 | 0.020 |
Why?
| Cyclins | 1 | 2006 | 38 | 0.020 |
Why?
| RNA, Neoplasm | 1 | 2006 | 44 | 0.020 |
Why?
| Proteoglycans | 1 | 2006 | 80 | 0.020 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2007 | 185 | 0.020 |
Why?
| Brain | 1 | 2013 | 1328 | 0.020 |
Why?
| Survivors | 1 | 2006 | 126 | 0.020 |
Why?
| Pregnancy | 1 | 2011 | 2607 | 0.010 |
Why?
| Lymphocyte Transfusion | 1 | 2003 | 10 | 0.010 |
Why?
| Probability | 1 | 2003 | 164 | 0.010 |
Why?
| Administration, Oral | 1 | 2003 | 426 | 0.010 |
Why?
| Tissue Donors | 1 | 2003 | 111 | 0.010 |
Why?
|
|
Van Rhee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|